The Future of Hypoparathyroidism Care: Research Priorities, Emerging Therapies, and Clinical Adoption of PTH Replacement

Looking ahead, the field of chronic hypoparathyroidism is on the cusp of broader adoption of PTH replacement and continued therapeutic innovation. In this final segment of the HCPLive Special Report, Sara Lubitz, MD, shares her vision for the next 5 to 10 years, beginning with a call to expand evidence for agents such as palopegteriparatide in populations that are currently understudied.

These include children and adolescents, as well as individuals who are pregnant or breastfeeding, for whom data on safety and long-term outcomes remain limited. She also points to the need for clear best practices in patients managing both hypoparathyroidism and comorbid conditions such as osteoporosis.

Lubitz identifies several critical research priorities that will shape future practice. Long-term studies are needed to clarify the impact of sustained PTH therapy on kidney function, cardiovascular disease, cognitive outcomes, and fracture risk. An important unanswered question is the degree to which the morbidity observed in chronic hypoparathyroidism—whether related to the disease itself or decades of conventional therapy—can be reversed or prevented with earlier and more physiologic PTH replacement. These data will be key in refining treatment algorithms and counseling patients about the long-range benefits and risks of therapy.

Finally, Lubitz notes that the therapeutic pipeline for hypoparathyroidism is increasingly active, with emerging agents targeting the PTH receptor or enhancing endogenous PTH through diverse mechanisms. Development programs are exploring daily, weekly, and potentially monthly injectable options, as well as oral approaches that could further decrease treatment burden.

Lubitz expresses optimism that PTH replacement will become the conventional standard for managing chronic hypoparathyroidism, relegating high-dose calcium and active vitamin D monotherapy to a more limited role as the field continues to evolve.